Business Context and Reporting Period
Oragenics, Inc. filed a Form 8-K on July 13, 2018, reporting the pricing of an underwritten public offering of units. The company is a Florida corporation focused on biopharmaceutical development.
Key Financial Metrics and Offering Details
- Gross Proceeds: $12 million (prior to deducting underwriting discounts, commissions, and offering expenses).
- Offering Price: $1.00 per unit.
- Units Issued:
- 2,636,000 Class A Units (1 common share + 1 seven-year warrant at $1.00 exercise price).
- 9,364,000 Class B Units (1 Series D Preferred share + 1 seven-year warrant at $1.00 exercise price).
- Total Securities: 2,636,000 common shares, 9,364,000 Series D preferred shares, and warrants to purchase up to 12,000,000 common shares.
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 1,800,000 additional shares and/or warrants.
- Expected Closing: On or about July 17, 2018.
The filing does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
This filing represents a significant capital raise event. The issuance of Series D Preferred stock includes a beneficial ownership blocker but carries no dividend rights (except if paid on common stock), no liquidation preference, and no voting rights. The securities are immediately separable.
Use of Proceeds and Outlook
Management anticipates using net proceeds for the following purposes:
- Funding the Phase II clinical trial for AG013 (treatment of Oral Mucositis).
- Pre-clinical development of the lantibiotics program.
- General corporate purposes, including R&D, capital expenditures, and working capital.
Ladenburg Thalmann & Co. Inc. serves as the sole book-running manager. The filing does not contain specific forward-looking guidance on financial performance or detailed risk factors beyond standard closing conditions.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting fees.
- Confirm the terms of the Series D Preferred stock regarding the beneficial ownership blocker.
- Monitor the exercise of the 45-day over-allotment option by underwriters.
- Review the progress of the AG013 Phase II clinical trial and lantibiotics program.